All News

JAMA study aims to determine whether financial barriers impact access to mental health services.

Dx&Vx identified multiple potential drug candidates using AI-based technology.

The two companies will continue to collaborate on the use of machine learning in improving precision medicine development.

This is the latest approval for Phathom Pharmaceutical’s GI treatment.

Novel drug 7MW3711 binds to tumor cell membrane antigens, being internalized and transported to the lysosome, releasing a cytotoxic drug, and inducing tumor cell apoptosis.

Treatment with CT-996 led to a significant placebo-adjusted mean weight loss of 6.1% within four weeks in participants with obesity but without type 2 diabetes.

The tech company’s data platform will be implemented into the genomic research department’s workflow.

The network includes organizations that represent over 45,000 agents and brokers.

Clearance of the NeuroLF Brain PET system marks Positrigo’s first device of its kind to be approved in the United States.

The agreement enables SOTIO to license multiple fully human bispecific antibodies from Biocytogen's RenLite platform.

The two companies will use Astrana’s technology offerings to improve access.

DSP-5336 targets the menin and mixed-lineage leukemia protein interaction, crucial in various biological processes, including cell growth and genomic stability.

Clearance of the New Drug Application for ART25.12 allows Artelo to begin a Phase I study for the drug in chemotherapy-induced peripheral neuropathy.

Congress and our nation’s public health officials should take the current moment to self-reflect and resolve challenges with public confidence in our public and scientific institutions.

Advancements in periodontal disease could make way for expansions in the dental space and other medical fields.

JAMA study aims to discover how weight loss differs between patients receiving tirzepatide compared with semaglutide among a clinical population of overweight of obese adults.

Avexitide has received Breakthrough Therapy Designation by the FDA for post-bariatric hypoglycemia, congenital hyperinsulinism, and more.

Empara’s virtual assistant is the latest attempt to use AI to simplify the user experience in the healthcare industry.

If you wish for your team to be diligent, innovative, and collaborative, you must first exhibit these traits yourself

According to the Complete Response Letter, the FDA has requested additional information on the manufacturing process and the type 1 diabetes indication for insulin icodec before completing its review.

Acquisition of Yellow Jersey Therapeutics includes access to NM26, a potential treatment for atopic dermatitis.

JAMA study evaluates changes to out-of-pocket costs and utilization of type 2 diabetes medications once patients reach the age of 65 years.

Zoryve is a steroid-free, once-daily treatment shown to offer rapid disease clearance and significant itch reduction for patients with mild to moderate atopic dermatitis.

A Harvard Business School Healthcare Alumni Association Q&A with Penn Center for Innovation’s Michael D. Moisel, MS, MBA.

The compounding pharmacy acquired Taylors Pharmacy and Key Compounding Pharmacy.

Body Vision’s AI-powered LungVision image system earned a place in Vizient’s innovative technology program.

Approval of the Mynx Control Venous vascular closure device was based on results from the ReliaSeal trial, which demonstrated 100% procedural and device success in cardiac ablation procedures.

Executives in the life sciences and medical device industries see promise in artificial intelligence (AI) and medical technologies, but must also navigate the changing healthcare ecosystem, varied stakeholder needs, and the impact of AI on market access and commercialization strategies.